Patient Diagnosed with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer Carcinoma In-Situ Treated Once with Light-Activated Ruvidar(TM) ...

The oral drug – Johnson & Johnson's Balversa (erdafitinib) – will become an option for adults with metastatic or unresectable ...

UroGen Pharma's potential remains strong despite market volatility, with promising FDA prospects for UGN-102 & a $5B ...

including Ferring's intravesical gene therapy Adstiladrin (nadofaragene firadenovec) and ImmunityBio's IL-15 receptor agonist Anktiva (nogapendekin alfa inbakicep), which both launched in the US ...

Dec. 10, 2024 — In a single IV injection, a gene therapy targeting cBIN1 can reverse the effects of heart failure and restore heart function in a large animal model. The therapy increases the ...

State-of-the-art treatment of OAB in 1999 includes tolterodine and oxybutynin XL as the first-line therapy. The economic costs of urinary incontinence have not been well studied. Direct costs ...

It is the first hospital and medical centre in the country to practice chemo-hyperthermia with the most treatment cases.

Correlation of Circulating Tumor DNA (ctDNA) Dynamics with Clinical Response in Muscle-Invasive Bladder Cancer (MIBC) Patients Undergoing Trimodality Therapy (TMT) Kent Mouw presented one of the first ...